Agenda – 5th Due Diligence Summit for Life Sciences

  • Day One
  • Day Two

Day One

 Tuesday, May 15, 2018 // Main Conference, Day One

8:45AM – 9:00AM

Chairperson’s Opening Remarks
Mike Myers, Senior Director, Lilly Research Labs — Due Diligence, ELI LILLY


9:00AM – 9:45AM

Key “Soft” Factors to Enable a Successful Collaboration
Martin Picard, Ph.D., Head, Search, Evaluation and Due Diligence, Biopharma R&D/External Innovation, MERCK KGAA

9:45AM – 10:30AM

Address Show-Stoppers Early on to Optimize the Due Diligence Process

10:30AM – 11:00AM

Networking Break

11:00AM – 11:45AM

Lead Effective Due Diligence to Inform Deal Decisions
Mike Myers, Senior Director, Lilly Research Labs — Due Diligence, ELI LILLY

11:45AM – 12:30PM

Optimize Your Diligence Projects Using the Right Tools
Shanker Shrestha, Head of Customer Success (US), INOVA SOFTWARE

12:30PM – 1:30PM



1:30PM – 2:15PM

The Strategic Value of an Efficient R&D-Commercial Interface During Clinical-Stage Due Diligence
Mike DeRidder, Global Head Oncology Cell Therapy Commercial Strategy, GLAXOSMITHKLINE
Marc S. Ballas, Medical Director, R&D, GLAXOSMITHKLINE

2:15PM – 3:00PM

Regulatory Affairs As a Strategic Partner in Licensing and Acquisition Processes
Paul Nitschmann, Executive Director, Regulatory Therapeutic Area Head, Cardiovascular, CNS, Bone, AMGEN

3:00PM – 3:30PM

Networking Break

3:30PM – 4:15PM

Case Study: The Spin on Spins
Rick Hoyt, Vice President, Business Development and Licensing, MALLINCKRODT

4:15PM – 5:00PM

Panel: Maximize Your Portfolio Value Through Out-Licensing and Product Divestitures
Alex Chang, Ph.D., Executive Director, Business Development, HELSINN THERAPEUTICS (U.S.)

Day Two

 Wednesday, May 16, 2018 // Main Conference, Day Two

8:00AM – 9:00AM

Continental Breakfast

9:00AM – 9:15AM

Chairperson’s Recap of Day One
Mike Myers, Senior Director, Lilly Research Labs — Due Diligence, ELI LILLY


9:15AM – 10:00AM

Key Questions to Ask When Evaluating Digital Health Targets
Rachel Sha, Head, Digital Business Development and Licensing, SANOFI

10:00AM – 10:45AM

Different Models of Collaboration for Working With Digital Health Companies
John Adamou, Vice President, Corporate and Business Development, RHEALTH

10:45AM – 11:15AM

Networking Break


11:15AM – 12:00PM

Plan for the Longevity of External Alliances
Jeffrey Warmke, Ph.D., Senior Vice President, External Scientific Affairs, DAIICHI SANKYO

12:00PM – 12:45PM

Integration of Alliance Management in the Deal-Making Process
Catherine Abbadie, Ph.D., Senior Director, Search, Evaluation and Alliance Management, Corporate Development and Licensing, SUNOVION PHARMACEUTICALS

12:45PM – 1:45PM


1:45PM – 2:30PM

Properly Value Non-Corporate Assets and Commercial Infrastructure
Walter Sandulli, MBA, Vice President, Business Development and Licensing (M&A), AKRIMAX PHARMACEUTICALS

2:30PM – 3:15PM

Optimize Synergy and Performance Post-Integration: A Playbook for Success
Rebecca Holland New, Group Vice President, Global Business Management, THERMO FISHER SCIENTIFIC

3:15PM – 3:30PM

Chairperson’s Closing Remarks
Mike Myers, Senior Director, Lilly Research Labs — Due Diligence, ELI LILLY